Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

8.4K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.4K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.9K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

357
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
357
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

1.8K
Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
1.8K
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

409
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
409
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics01:11

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics

442
All neuromuscular blocking agents are injected intravenously because they are poorly absorbed from the GI tract. Rapid onset is achieved with intravenous administration, although absorption is also adequate from an intramuscular injection. Since these agents are highly ionized, they do not readily penetrate cell membranes or cross the blood-brain barrier.
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...
442

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Identification of the entosis stages in situ in lung cancer tissue and their changes after neoadjuvant chemotherapy].

Arkhiv patologii·2026
Same author

[Vascular dysfunction: Processes Caused by aging, approaches to restorative therapy and prevention (part 2).]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

[TRPS1 as a novel immunohistochemical marker in breast cancer diagnosis].

Arkhiv patologii·2026
Same author

[Vascular dysfunction: processes due to aging, approaches to restorative therapy and prevention (part 1).]

Advances in gerontology = Uspekhi gerontologii·2026
Same author

From heterogeneity to hope: emerging markers in triple-negative breast cancer research.

Medical oncology (Northwood, London, England)·2025
Same author

[Prognostic value of molecular markers IDO1, DCLK1 and FOXC1 in Triple-negative breast cancer: morphological and clinical correlations].

Arkhiv patologii·2025
Same journal

Reaction of the Blood System of ICR Mice with Traumatic Brain Injury.

Bulletin of experimental biology and medicine·2026
Same journal

Antidepressant Activity of 11-Dialkylaminoethyl-2,3,4,5-tetrahydrodiazepino[1,2-a]benzimidazole Derivative DAB-21 in a Model of Chronic Unpredictable Mild Stress.

Bulletin of experimental biology and medicine·2026
Same journal

Colon Adenocarcinoma Cell-Derived Galectins-1,3 Modulate Differentiation of CD4<sup>+</sup> T Lymphocytes In Vitro.

Bulletin of experimental biology and medicine·2026
Same journal

Circulating DNA-Markers of High Risk for Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease.

Bulletin of experimental biology and medicine·2026
Same journal

Study of Anxiolytic Properties of Diterpene Alkaloid 12-Epinapelline N-Oxide.

Bulletin of experimental biology and medicine·2026
Same journal

Ethylmethylhydroxypyridine Succinate Limits Inflammatory-Degenerative Changes in the Hypothalamus and Corrects Disturbances in the Circadian Rhythm of Corticosterone Secretion in Aged Rats.

Bulletin of experimental biology and medicine·2026
See all related articles

Related Experiment Video

Updated: Jun 23, 2025

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.0K

Xenon Antiaggregant Effects.

V V Udut1,2, D V Tsuran1, S A Naumov1

  • 1E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.

Bulletin of Experimental Biology and Medicine
|June 18, 2024
PubMed
Summary
This summary is machine-generated.

Xenon gas (Xe) significantly reduces platelet aggregation, both spontaneous and induced by common agonists. This finding suggests potential therapeutic applications for xenon in managing platelet-related conditions.

Keywords:
xenon; platelets; aggregation; aggregation inducers

More Related Videos

Hyperpolarized Xenon for NMR and MRI Applications
16:20

Hyperpolarized Xenon for NMR and MRI Applications

Published on: September 6, 2012

19.5K
Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology
10:52

Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology

Published on: April 23, 2019

12.9K

Related Experiment Videos

Last Updated: Jun 23, 2025

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers
14:52

Recording Brain Electromagnetic Activity During the Administration of the Gaseous Anesthetic Agents Xenon and Nitrous Oxide in Healthy Volunteers

Published on: January 13, 2018

11.0K
Hyperpolarized Xenon for NMR and MRI Applications
16:20

Hyperpolarized Xenon for NMR and MRI Applications

Published on: September 6, 2012

19.5K
Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology
10:52

Evaluation of Synaptic Multiplicity Using Whole-cell Patch-clamp Electrophysiology

Published on: April 23, 2019

12.9K

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Background:

  • Platelet aggregation plays a crucial role in hemostasis and thrombosis.
  • Disruptions in platelet function are implicated in various cardiovascular and bleeding disorders.
  • Novel therapeutic agents targeting platelet activity are continuously sought.

Purpose of the Study:

  • To investigate the in vitro effects of xenon (Xe) on platelet aggregation.
  • To determine the impact of xenon on spontaneous and agonist-induced platelet aggregation.

Main Methods:

  • An in vitro model using platelet-enriched blood plasma.
  • Induction of platelet aggregation using collagen, ADP, ristocetin, and epinephrine.
  • Measurement of platelet aggregation in the presence of millimolar concentrations of xenon.

Main Results:

  • Xenon significantly decreased collagen-induced (≈30%) and ADP-induced (≈25%) platelet aggregation.
  • Xenon also reduced ristocetin-induced (≈12%) and epinephrine-induced (≈9%) aggregation.
  • Spontaneous platelet aggregation was decreased twofold by xenon.

Conclusions:

  • Xenon exhibits potent anti-aggregatory effects on platelets in vitro.
  • Xenon's mechanism may involve membrane lipid interactions and NMDA receptor blockade.
  • These findings highlight xenon's potential as a therapeutic agent for platelet dysfunction.